Simvastatin

Phase 3UNKNOWN
1 views this week 0 watching💤 Quiet
Interest: 33/100
33
Hype Score

Development Stage

Pre-clinical
Phase 1
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Relapsing Remitting Multiple Sclerosis

Conditions

Relapsing Remitting Multiple Sclerosis

Trial Timeline

Oct 1, 2005 → —

About Simvastatin

Simvastatin is a phase 3 stage product being developed by Biogen for Relapsing Remitting Multiple Sclerosis. The current trial status is unknown. This product is registered under clinical trial identifier NCT00242268. Target conditions include Relapsing Remitting Multiple Sclerosis.

What happened to similar drugs?

20 of 20 similar drugs in Relapsing Remitting Multiple Sclerosis were approved

Approved (20) Terminated (2) Active (0)
Rebif® + Rebif®MerckApproved
Interferon beta-1aMerckApproved
Rebif® (clone 484-39)MerckApproved
RebifMerckApproved
Fingolimod 0.5 mgNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
4
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT00242268Phase 3UNKNOWN